Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Surgical leadership: the British concept.

Primrose JN.

Innov Surg Sci. 2019 May 10;4(2):65-67. doi: 10.1515/iss-2019-0006. eCollection 2019 Jun.

2.

The Miami International Evidence-Based Guidelines on Minimally Invasive Pancreas Resection.

Asbun HJ, Moekotte AL, Vissers FL, Kunzler F, Cipriani F, Alseidi A, D'Angelica MI, Balduzzi A, Bassi C, Björnsson B, Boggi U, Callery MP, Del Chiaro M, Coimbra FJ, Conrad C, Cook A, Coppola A, Dervenis C, Dokmak S, Edil BH, Edwin B, Giulianotti PC, Han HS, Hansen PD, van der Heijde N, van Hilst J, Hester CA, Hogg ME, Jarufe N, Jeyarajah DR, Keck T, Kim SC, Khatkov IE, Kokudo N, Kooby DA, Korrel M, de Leon FJ, Lluis N, Lof S, Machado MA, Demartines N, Martinie JB, Merchant NB, Molenaar IQ, Moravek C, Mou YP, Nakamura M, Nealon WH, Palanivelu C, Pessaux P, Pitt HA, Polanco PM, Primrose JN, Rawashdeh A, Sanford DE, Senthilnathan P, Shrikhande SV, Stauffer JA, Takaori K, Talamonti MS, Tang CN, Vollmer CM, Wakabayashi G, Walsh RM, Wang SE, Zinner MJ, Wolfgang CL, Zureikat AH, Zwart MJ, Conlon KC, Kendrick ML, Zeh HJ, Hilal MA, Besselink MG; International Study Group on Minimally Invasive Pancreas Surgery (I-MIPS).

Ann Surg. 2019 Sep 16. doi: 10.1097/SLA.0000000000003590. [Epub ahead of print]

PMID:
31567509
3.

Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC.

Sreekumar R, Emaduddin M, Al-Saihati H, Moutasim K, Chan J, Spampinato M, Bhome R, Yuen HM, Mescoli C, Vitale A, Cillo U, Rugge M, Primrose J, Hilal MA, Thirdborough S, Tulchinsky E, Thomas G, Mirnezami A, Sayan AE.

Cell Death Dis. 2019 Sep 23;10(10):703. doi: 10.1038/s41419-019-1885-6.

4.

Evaluation and management of incidental gallbladder cancer.

Zaidi MY, Abou-Alfa GK, Ethun CG, Shrikhande SV, Goel M, Nervi B, Primrose J, Valle JW, Maithel SK.

Chin Clin Oncol. 2019 Aug;8(4):37. doi: 10.21037/cco.2019.07.01. Epub 2019 Aug 5.

5.

Hepatic Resection Following Selective Internal Radiation Therapy for Colorectal Cancer Metastases in the FOXFIRE Clinical Trial: Clinical Outcomes and Distribution of Microspheres.

Winter H, Rassam J, Virdee PS, Goldin R, Pitcheshwar P, Weaver K, Primrose J, Berry DP, Wasan HS, Sharma RA.

Cancers (Basel). 2019 Aug 12;11(8). pii: E1155. doi: 10.3390/cancers11081155.

6.

Population-based observational study of acute pancreatitis in southern England.

PanWessex Study Group; Wessex Surgical Trainee Research Collaborative, Mirnezami A, Knight B, Moran B, Noble F, Branagan G, Primrose J, Pearson K, West M, Curtis N, Pucher P, Cuttress R, Pugh S, Underwood T.

Ann R Coll Surg Engl. 2019 Sep;101(7):487-494. doi: 10.1308/rcsann.2019.0055. Epub 2019 Jul 30.

PMID:
31362520
7.

Development and validation of a model to predict outcomes of colon cancer surveillance.

Rose J, Homa L, Kong CY, Cooper GS, Kattan MW, Ermlich BO, Meyers JP, Primrose JN, Pugh SA, Shinkins B, Kim U, Meropol NJ.

Cancer Causes Control. 2019 Jul;30(7):767-778. doi: 10.1007/s10552-019-01187-x. Epub 2019 May 25.

PMID:
31129907
8.

Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery.

West MA, van Dijk DPJ, Gleadowe F, Reeves T, Primrose JN, Abu Hilal M, Edwards MR, Jack S, Rensen SSS, Grocott MPW, Levett DZH, Olde Damink SWM.

J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):860-871. doi: 10.1002/jcsm.12433. Epub 2019 May 21.

9.

Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial.

Shinkins B, Primrose JN, Pugh SA, Nicholson BD, Perera R, James T, Man D.

Br J Surg. 2019 May;106(6):728. doi: 10.1002/bjs.11175. No abstract available.

PMID:
30973997
10.

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group.

Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25. Erratum in: Lancet Oncol. 2019 Apr 2;:.

PMID:
30922733
11.

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.

Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK.

J Clin Oncol. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11.

PMID:
30856044
12.

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Rogerson C, Bleaney CW, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2019 Jan 22;9(1):318. doi: 10.1038/s41598-018-37591-7.

13.

Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.

Sreekumar R, Harris S, Moutasim K, DeMateos R, Patel A, Emo K, White S, Yagci T, Tulchinsky E, Thomas G, Primrose JN, Sayan AE, Mirnezami AH.

JAMA Netw Open. 2018 Oct 5;1(6):e183115. doi: 10.1001/jamanetworkopen.2018.3115.

14.

Consensus and controversies regarding follow-up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology.

Bastiaenen VP, Hovdenak Jakobsen I, Labianca R, Martling A, Morton DG, Primrose JN, Tanis PJ, Laurberg S; Research Committee and the Guidelines Committee of the European Society of Coloproctology (ESCP).

Colorectal Dis. 2019 Apr;21(4):392-416. doi: 10.1111/codi.14503. Epub 2019 Jan 3. Review.

PMID:
30506553
15.

Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence.

O'Reilly D, Fou L, Hasler E, Hawkins J, O'Connell S, Pelone F, Callaway M, Campbell F, Capel M, Charnley R, Corrie P, Elliot D, Goodburn L, Jewell A, Joharchi S, McGeeney L, Mukherjee S, Oppong K, Whelan P, Primrose J, Neoptolemos J.

Pancreatology. 2018 Dec;18(8):962-970. doi: 10.1016/j.pan.2018.09.012. Epub 2018 Sep 28. Review.

PMID:
30292643
16.

The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer.

Gootjes EC, Bakkerus L, Ten Tije AJ, Witteveen PO, Buffart TE, Bridgewater JA, Primrose JN, Verhoef C, Verheul HMW.

Eur J Cancer. 2018 Nov;103:160-164. doi: 10.1016/j.ejca.2018.07.012. Epub 2018 Sep 19.

PMID:
30243064
17.

Surgeons' assessment versus risk models for predicting complications of hepato-pancreato-biliary surgery (HPB-RISC): a multicenter prospective cohort study.

Samim M, Mungroop TH, AbuHilal M, Isfordink CJ, Molenaar QI, van der Poel MJ, Armstrong TA, Takhar AS, Pearce NW, Primrose JN, Harris S, Verkooijen HM, van Gulik TM, Hagendoorn J, Busch OR, Johnson CD, Besselink MG; HPB-RISC Study Group.

HPB (Oxford). 2018 Sep;20(9):809-814. doi: 10.1016/j.hpb.2018.02.635. Epub 2018 Apr 17.

18.

Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial.

Shinkins B, Primrose JN, Pugh SA, Nicholson BD, Perera R, James T, Mant D.

Br J Surg. 2018 May;105(6):658-662. doi: 10.1002/bjs.10819. Epub 2018 Mar 26. Erratum in: Br J Surg. 2019 May;106(6):728.

19.

Laparoscopic versus open major hepatectomy: a systematic review and meta-analysis of individual patient data.

Kasai M, Cipriani F, Gayet B, Aldrighetti L, Ratti F, Sarmiento JM, Scatton O, Kim KH, Dagher I, Topal B, Primrose J, Nomi T, Fuks D, Abu Hilal M.

Surgery. 2018 May;163(5):985-995. doi: 10.1016/j.surg.2018.01.020. Epub 2018 Mar 16. Review.

PMID:
29555197
20.

Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk.

Del Vecchio F, Lee GH, Hawezi J, Bhome R, Pugh S, Sayan E, Thomas G, Packham G, Primrose J, Pichler M, Mirnezami A, Calin G, Bullock M.

Cancer Lett. 2018 May 1;421:94-102. doi: 10.1016/j.canlet.2018.02.022. Epub 2018 Feb 17.

PMID:
29458141
21.

Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer.

Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE, Mirnezami AH.

Cancer Lett. 2018 Apr 28;420:228-235. doi: 10.1016/j.canlet.2018.02.002. Epub 2018 Feb 7. Review.

22.

Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression.

Bhome R, Goh RW, Bullock MD, Pillar N, Thirdborough SM, Mellone M, Mirnezami R, Galea D, Veselkov K, Gu Q, Underwood TJ, Primrose JN, De Wever O, Shomron N, Sayan AE, Mirnezami AH.

Aging (Albany NY). 2017 Dec 28;9(12):2666-2694. doi: 10.18632/aging.101355.

23.

Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.

Pugh S, Thiébaut R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, Laurent-Puig P.

Oncotarget. 2017 Sep 27;8(55):93856-93866. doi: 10.18632/oncotarget.21291. eCollection 2017 Nov 7.

24.

Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study.

van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, Alseidi A, Ateeb Z, Balzano G, Berrevoet F, Björnsson B, Boggi U, Busch OR, Butturini G, Casadei R, Del Chiaro M, Chikhladze S, Cipriani F, van Dam R, Damoli I, van Dieren S, Dokmak S, Edwin B, van Eijck C, Fabre JM, Falconi M, Farges O, Fernández-Cruz L, Forgione A, Frigerio I, Fuks D, Gavazzi F, Gayet B, Giardino A, Groot Koerkamp B, Hackert T, Hassenpflug M, Kabir I, Keck T, Khatkov I, Kusar M, Lombardo C, Marchegiani G, Marshall R, Menon KV, Montorsi M, Orville M, de Pastena M, Pietrabissa A, Poves I, Primrose J, Pugliese R, Ricci C, Roberts K, Røsok B, Sahakyan MA, Sánchez-Cabús S, Sandström P, Scovel L, Solaini L, Soonawalla Z, Souche FR, Sutcliffe RP, Tiberio GA, Tomazic A, Troisi R, Wellner U, White S, Wittel UA, Zerbi A, Bassi C, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS).

Ann Surg. 2019 Jan;269(1):10-17. doi: 10.1097/SLA.0000000000002561.

PMID:
29099399
25.

The Southampton Consensus Guidelines for Laparoscopic Liver Surgery: From Indication to Implementation.

Abu Hilal M, Aldrighetti L, Dagher I, Edwin B, Troisi RI, Alikhanov R, Aroori S, Belli G, Besselink M, Briceno J, Gayet B, D'Hondt M, Lesurtel M, Menon K, Lodge P, Rotellar F, Santoyo J, Scatton O, Soubrane O, Sutcliffe R, Van Dam R, White S, Halls MC, Cipriani F, Van der Poel M, Ciria R, Barkhatov L, Gomez-Luque Y, Ocana-Garcia S, Cook A, Buell J, Clavien PA, Dervenis C, Fusai G, Geller D, Lang H, Primrose J, Taylor M, Van Gulik T, Wakabayashi G, Asbun H, Cherqui D.

Ann Surg. 2018 Jul;268(1):11-18. doi: 10.1097/SLA.0000000000002524.

26.

Are the current difficulty scores for laparoscopic liver surgery telling the whole story? An international survey and recommendations for the future.

Halls MC, Cherqui D, Taylor MA, Primrose JN, Abu Hilal M; Collaborators of The Difficulty of Laparoscopic Liver Surgery Survey.

HPB (Oxford). 2018 Mar;20(3):231-236. doi: 10.1016/j.hpb.2017.08.028. Epub 2017 Sep 29.

27.

IL-12 and IL-15 induce the expression of CXCR6 and CD49a on peripheral natural killer cells.

Hydes T, Noll A, Salinas-Riester G, Abuhilal M, Armstrong T, Hamady Z, Primrose J, Takhar A, Walter L, Khakoo SI.

Immun Inflamm Dis. 2018 Mar;6(1):34-46. doi: 10.1002/iid3.190. Epub 2017 Sep 27.

28.

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Sep;2(9):e6.

29.

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.

Mant D, Gray A, Pugh S, Campbell H, George S, Fuller A, Shinkins B, Corkhill A, Mellor J, Dixon E, Little L, Perera-Salazar R, Primrose J.

Health Technol Assess. 2017 May;21(32):1-86. doi: 10.3310/hta21320.

30.

What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial.

Shinkins B, Nicholson BD, James T, Pathiraja I, Pugh S, Perera R, Primrose J, Mant D.

Health Technol Assess. 2017 Apr;21(22):1-60. doi: 10.3310/hta21220. Review.

31.

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer.

West MA, Roman A, Sayan E, Primrose JN, Wedge SR, Underwood TJ, Mirnezami AH.

Crit Rev Oncol Hematol. 2017 Apr;112:80-102. doi: 10.1016/j.critrevonc.2017.02.008. Epub 2017 Feb 16. Review.

PMID:
28325268
32.

The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial.

Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Pugh S, Mant D.

PLoS One. 2017 Mar 10;12(3):e0171810. doi: 10.1371/journal.pone.0171810. eCollection 2017.

33.

Outcome and Learning Curve in 159 Consecutive Patients Undergoing Total Laparoscopic Hemihepatectomy.

van der Poel MJ, Besselink MG, Cipriani F, Armstrong T, Takhar AS, van Dieren S, Primrose JN, Pearce NW, Abu Hilal M.

JAMA Surg. 2016 Oct 1;151(10):923-928. doi: 10.1001/jamasurg.2016.1655.

PMID:
27383568
34.

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.

Garcia E, Hayden A, Birts C, Britton E, Cowie A, Pickard K, Mellone M, Choh C, Derouet M, Duriez P, Noble F, White MJ, Primrose JN, Strefford JC, Rose-Zerilli M, Thomas GJ, Ang Y, Sharrocks AD, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Sci Rep. 2016 Sep 7;6:32417. doi: 10.1038/srep32417. Erratum in: Sci Rep. 2019 Jan 22;9(1):318.

35.

Propensity score-based analysis of outcomes of laparoscopic versus open liver resection for colorectal metastases.

Cipriani F, Rawashdeh M, Stanton L, Armstrong T, Takhar A, Pearce NW, Primrose J, Abu Hilal M.

Br J Surg. 2016 Oct;103(11):1504-12. doi: 10.1002/bjs.10211. Epub 2016 Aug 3.

PMID:
27484847
36.

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.

Pugh SA, Bowers M, Ball A, Falk S, Finch-Jones M, Valle JW, O'Reilly DA, Siriwardena AK, Hornbuckle J, Rees M, Rees C, Iveson T, Hickish T, Maishman T, Stanton L, Dixon E, Corkhill A, Radford M, Garden OJ, Cunningham D, Maughan TS, Bridgewater JA, Primrose JN.

Br J Cancer. 2016 Aug 9;115(4):420-4. doi: 10.1038/bjc.2016.208. Epub 2016 Jul 19.

37.

Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.

Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, Sayan AE, Mirnezami AH.

New Horiz Transl Med. 2016 Jan;3(1):9-21.

38.

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.

Noble F, Mellows T, McCormick Matthews LH, Bateman AC, Harris S, Underwood TJ, Byrne JP, Bailey IS, Sharland DM, Kelly JJ, Primrose JN, Sahota SS, Bateman AR, Thomas GJ, Ottensmeier CH.

Cancer Immunol Immunother. 2016 Jun;65(6):651-62. doi: 10.1007/s00262-016-1826-5. Epub 2016 Mar 28.

39.

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

Matthews LM, Noble F, Tod J, Jaynes E, Harris S, Primrose JN, Ottensmeier C, Thomas GJ, Underwood TJ.

Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.460. No abstract available.

40.

Blood CEA levels for detecting recurrent colorectal cancer.

Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, Perera R, Primrose JN, Mant D.

Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134. doi: 10.1002/14651858.CD011134.pub2. Review.

41.

Natural killer cell maturation markers in the human liver and expansion of an NKG2C+KIR+ population.

Hydes T, Abuhilal M, Armstrong T, Primrose J, Takhar A, Khakoo S.

Lancet. 2015 Feb 26;385 Suppl 1:S45. doi: 10.1016/S0140-6736(15)60360-9.

PMID:
26312867
42.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial.

Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H.

BMC Cancer. 2015 Jul 31;15:564. doi: 10.1186/s12885-015-1498-0.

43.

Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial.

Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D, Primrose JN.

Ann Surg. 2016 Jun;263(6):1143-7. doi: 10.1097/SLA.0000000000001351.

44.

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

McCormick Matthews LH, Noble F, Tod J, Jaynes E, Harris S, Primrose JN, Ottensmeier C, Thomas GJ, Underwood TJ.

Br J Cancer. 2015 Jun 30;113(1):107-18. doi: 10.1038/bjc.2015.179. Epub 2015 Jun 25. Review. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746.

45.

A top-down view of the tumor microenvironment: structure, cells and signaling.

Bhome R, Bullock MD, Al Saihati HA, Goh RW, Primrose JN, Sayan AE, Mirnezami AH.

Front Cell Dev Biol. 2015 May 29;3:33. doi: 10.3389/fcell.2015.00033. eCollection 2015. Review.

46.

Clinician engagement is critical to public engagement with clinical trials.

Stock CJ, Carley N, Hickman B, Primrose J, Ayres A, McGrath C, Edwards CJ, Faust SN.

BMJ. 2015 Jun 12;350:h3140. doi: 10.1136/bmj.h3140. No abstract available.

PMID:
26071322
47.

Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases.

Primrose JN, Cunningham D, Garden OJ, Maughan TS, Pugh SA, Stanton L, Falk SJ, Rees M, Finch-Jones M, Valle JW, O'Reilly D, Hornbuckle J, Hickish T, Bridgewater JA.

J Clin Oncol. 2015 Jul 20;33(21):2405-6. doi: 10.1200/JCO.2014.60.1344. Epub 2015 Jun 1. No abstract available.

PMID:
26033821
48.

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.

Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose J, Packham G, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami A, Calin GA, Nicoloso MS.

Gut. 2016 Jun;65(6):977-989. doi: 10.1136/gutjnl-2015-309372. Epub 2015 Mar 24.

49.

Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.

Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH.

Oncotarget. 2015 Mar 30;6(9):7262-79.

50.

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma.

Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, Thirdborough S, Mead A, Clemons N, Mellone M, Uzoho C, Primrose JN, Blaydes JP, Thomas GJ.

J Pathol. 2015 Feb;235(3):466-77. doi: 10.1002/path.4467.

Supplemental Content

Loading ...
Support Center